Linagliptin

Linagliptin is an oral antidiabetic belongs to a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It acts by inhibiting the enzyme (dipeptidyl peptidase-4; DPP-4) which prevents the breakdown of substances called as incretins, ultimately increasing the production of insulin that reduces blood glucose level at fasting and after intake of food.